{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IV+Non-small+Cell+Lung+Cancer+%28NSCLC%29&page=26",
    "query": {
      "condition": "Stage IV Non-small Cell Lung Cancer (NSCLC)",
      "page": 26
    },
    "page_size": 10
  },
  "pagination": {
    "page": 26,
    "page_size": 10,
    "total_count": 1155,
    "total_pages": 116,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IV+Non-small+Cell+Lung+Cancer+%28NSCLC%29&page=27&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IV+Non-small+Cell+Lung+Cancer+%28NSCLC%29&page=25&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T19:24:46.121Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06567015",
      "title": "Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer (NSCLC)"
      ],
      "interventions": [
        {
          "name": "STX-241",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pierre Fabre Medicament",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 171,
      "start_date": "2024-09-17",
      "completion_date": "2030-07",
      "has_results": false,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-10-15T19:24:46.121Z",
      "location_count": 2,
      "location_summary": "Nashville, Tennessee • Houston, Texas",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06567015"
    },
    {
      "nct_id": "NCT07227025",
      "title": "A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "Amivantamab",
          "type": "DRUG"
        },
        {
          "name": "Olomorasib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2026-03-03",
      "completion_date": "2029-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-10-15T19:24:46.121Z",
      "location_count": 2,
      "location_summary": "New York, New York • Fairfax, Virginia",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07227025"
    },
    {
      "nct_id": "NCT02514174",
      "title": "Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung",
        "ErbB Receptors"
      ],
      "interventions": [
        {
          "name": "Afatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "70 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "70 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2015-08-18",
      "completion_date": "2019-04-25",
      "has_results": true,
      "last_update_posted_date": "2020-03-30",
      "last_synced_at": "2026-10-15T19:24:46.121Z",
      "location_count": 10,
      "location_summary": "Scottsdale, Arizona • Anaheim, California • Duarte, California + 7 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02514174"
    },
    {
      "nct_id": "NCT05908799",
      "title": "Emulation of the KEYNOTE-189 Trial Using Electronic Health Records",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Non-small Cell Lung Cancer",
        "Metastatic Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab + Pemetrexed-Platinum",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed-Platinum",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aetion, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1854,
      "start_date": "2023-06-05",
      "completion_date": "2023-08-31",
      "has_results": false,
      "last_update_posted_date": "2023-09-13",
      "last_synced_at": "2026-10-15T19:24:46.121Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05908799"
    },
    {
      "nct_id": "NCT00074204",
      "title": "Gemcitabine and Carboplatin Followed By Docetaxel in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2003-10",
      "completion_date": "2008-04",
      "has_results": false,
      "last_update_posted_date": "2010-08-16",
      "last_synced_at": "2026-10-15T19:24:46.121Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00074204"
    },
    {
      "nct_id": "NCT07250477",
      "title": "Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer Stage IIIC",
        "Non-small Cell Lung Cancer Stage IV",
        "Non Small Cell Lung Cancer",
        "Non-small Cell Lung Cancer Metastatic",
        "Non-small Cell Lung Cancer Unresectable"
      ],
      "interventions": [
        {
          "name": "Systemic (ICI)-based therapy informed by the PROphet CB assay and the CARG-TT assessment.",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2026-01-30",
      "completion_date": "2036-12",
      "has_results": false,
      "last_update_posted_date": "2026-08-25",
      "last_synced_at": "2026-10-15T19:24:46.121Z",
      "location_count": 4,
      "location_summary": "Chico, California • Marysville, California • Sacramento, California + 1 more",
      "locations": [
        {
          "city": "Chico",
          "state": "California"
        },
        {
          "city": "Marysville",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Truckee",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07250477"
    },
    {
      "nct_id": "NCT03353675",
      "title": "A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer Metastatic"
      ],
      "interventions": [
        {
          "name": "TG4010",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Transgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2018-01-05",
      "completion_date": "2021-02-17",
      "has_results": true,
      "last_update_posted_date": "2022-01-11",
      "last_synced_at": "2026-10-15T19:24:46.121Z",
      "location_count": 2,
      "location_summary": "Charlotte, North Carolina • Nashville, Tennessee",
      "locations": [
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03353675"
    },
    {
      "nct_id": "NCT05361174",
      "title": "A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Unresectable Melanoma",
        "Metastatic Melanoma",
        "Stage III Non-small Cell Lung Cancer",
        "Stage IV Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "IOV-4001",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Iovance Biotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 53,
      "start_date": "2022-07-20",
      "completion_date": "2029-09",
      "has_results": false,
      "last_update_posted_date": "2026-06-11",
      "last_synced_at": "2026-10-15T19:24:46.121Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • Miami, Florida • Orlando, Florida + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05361174"
    },
    {
      "nct_id": "NCT03825510",
      "title": "Immunotherapy SBRT Sensitization of the Programmed Death-1 (PD-1) Effect",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Nonsmall Cell Lung Cancer",
        "Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Stereotactic Body Radiotherapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Crozer-Keystone Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2017-04-28",
      "completion_date": "2022-03-08",
      "has_results": false,
      "last_update_posted_date": "2023-03-06",
      "last_synced_at": "2026-10-15T19:24:46.121Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03825510"
    },
    {
      "nct_id": "NCT03050060",
      "title": "Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Kidney Carcinoma",
        "Recurrent Lung Non-Small Cell Carcinoma",
        "Stage IV Cutaneous Melanoma AJCC v6 and v7",
        "Stage IV Renal Cell Cancer AJCC v7",
        "Stage IV Lung Non-Small Cell Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Hypofractionated Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nelfinavir Mesylate",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2017-06-09",
      "completion_date": "2020-07-12",
      "has_results": true,
      "last_update_posted_date": "2022-06-22",
      "last_synced_at": "2026-10-15T19:24:46.121Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03050060"
    }
  ]
}